pros and cons of glp-1 agonists Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) receptor (semaglutide [Wegovy, Ozempic, Rybelsus]) dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind Mapping the effectiveness and risks

Since the amount of active ingredients can vary from batch to batch, its difficult to predict how your body will react, increasing the risk of harmful side effects

GLP-1 receptors sit in the heart muscle itself

Phosphorylation of key signaling proteins like Akt, mTOR, and S6K occurs rapidly and can be measured using cell-level biology techniques

RA inhibits the development of Th1 cells and promotes the development of Th2 cells

Answer: After age 30, adults may lose between 3% to 8% muscle mass each decade, and the rate of muscle loss may accelerate after age 60 (Volpi, Curr Opin Clin Nutr Metab Care 2018)

This doesn't mean they're dangerous or ineffective, but it does mean: Limited clinical data: Without the trials required for approval, human data remains sparse